Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.

International journal of molecular sciences - 1 Jan 2010

Maeda Daichi, Mao Tsui-Lien, Fukayama Masashi, Nakagawa Shunsuke, Yano Tetsu, Taketani Yuji, Shih Ie-Ming

Abstract excerpt

Recent genome-wide analysis has demonstrated that somatic mutations in ARID1A (BAF250) are the most common molecular genetic changes in ovarian clear cell carcinoma (OCCC). ARID1A mutations, which occur in approximately half of OCCC cases, lead to deletion of the encoded protein and inactivation of the putative tumor suppressor. In this study, we determined the significance of loss of ARID1A immunoreactivity with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Age Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Immunohistochemistry

Share to Nuclear Proteins

Share to Ovarian Neoplasms

Share to Survival Rate

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21614196
DOI: 10.3390/ijms11125120
PMCID: PMC3100854

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.PMID 21614196Read ↗

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.Semantic proximity Read ↗

Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian CancersSemantic proximity Read ↗

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovarySemantic proximity Read ↗

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.Semantic proximity Read ↗

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.Semantic proximity Read ↗

ARID1A mutations in endometriosis-associated ovarian carcinomas.Semantic proximity Read ↗

Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot AssessmentSemantic proximity Read ↗

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Translational genomics of ovarian clear cell carcinoma.Semantic proximity Read ↗

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaSemantic proximity Read ↗

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.